Cynata Therapeutics Ltd banner

Cynata Therapeutics Ltd
ASX:CYP

Watchlist Manager
Cynata Therapeutics Ltd Logo
Cynata Therapeutics Ltd
ASX:CYP
Watchlist
Price: 0.3 AUD Market Closed
Market Cap: AU$71.2m

Multiples-Based Value

The Multiples-Based Value of one CYP stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.3 AUD, Cynata Therapeutics Ltd is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CYP Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

CYP Competitors Multiples
Cynata Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Cynata Therapeutics Ltd
ASX:CYP
71.2m AUD 350.2 -8.5 -8.2 -8.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
373.2B USD 6.1 89.4 14.8 20.6
US
Exact Sciences Corp
NASDAQ:EXAS
355.4B USD 6.2 -96.2 951.3 -107.4
US
Amgen Inc
NASDAQ:AMGN
190.4B USD 5.1 24.5 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
169.9B USD 5.7 19.8 12.4 15.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.3 28.1 21.1 22
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80B USD 5.5 17.4 12.9 14.7
AU
CSL Ltd
ASX:CSL
69.6B AUD 3.2 34.9 11.5 14.4
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
AU
Cynata Therapeutics Ltd
ASX:CYP
Average P/S: 3 063 034.1
350.2
123%
2.8
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Exact Sciences Corp
NASDAQ:EXAS
6.2
12%
0.5
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.7
5%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.3
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.5
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
AU
Cynata Therapeutics Ltd
ASX:CYP
Average P/E: 35.7
Negative Multiple: -8.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.4
97%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -96.2 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.5
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.8
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
AU
CSL Ltd
ASX:CSL
34.9
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Cynata Therapeutics Ltd
ASX:CYP
Average EV/EBITDA: 148.3
Negative Multiple: -8.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Exact Sciences Corp
NASDAQ:EXAS
951.3
261%
3.6
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.1
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
18%
0.7
AU
CSL Ltd
ASX:CSL
11.5
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Cynata Therapeutics Ltd
ASX:CYP
Average EV/EBIT: 16.9
Negative Multiple: -8.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.6
23%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -107.4 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.3
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.7
23%
0.6
AU
CSL Ltd
ASX:CSL
14.4
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett